These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16103502)

  • 21. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Smith ER
    Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
    [No Abstract]   [Full Text] [Related]  

  • 22. Discontinuation of Vioxx.
    Nutt DJ
    Lancet; 2005 Jan 1-7; 365(9453):28. PubMed ID: 15639676
    [No Abstract]   [Full Text] [Related]  

  • 23. Perspectives on drug withdrawals.
    Williams R
    CMAJ; 2005 Jul; 173(2):129. PubMed ID: 16027417
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors.
    Couzin J
    Science; 2004 Oct; 306(5695):384-5. PubMed ID: 15486258
    [No Abstract]   [Full Text] [Related]  

  • 25. The Vioxx debacle.
    Alpert JS
    Am J Med; 2005 Mar; 118(3):203-4. PubMed ID: 15745713
    [No Abstract]   [Full Text] [Related]  

  • 26. The Vioxx debacle revisited.
    Manthous CA
    Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904
    [No Abstract]   [Full Text] [Related]  

  • 27. The Vioxx debacle revisited.
    Mohapatra PR; Janmeja AK
    Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909
    [No Abstract]   [Full Text] [Related]  

  • 28. A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework.
    Lynd LD; Marra CA; Najafzadeh M; Sadatsafavi M
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1172-80. PubMed ID: 20602338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discontinuation of Vioxx.
    Garattini S; Bertelé V
    Lancet; 2005 Jan 1-7; 365(9453):24. PubMed ID: 15639671
    [No Abstract]   [Full Text] [Related]  

  • 30. Merck cleared in personal injury case against Vioxx.
    Mayor S
    BMJ; 2005 Nov; 331(7525):1101. PubMed ID: 16282390
    [No Abstract]   [Full Text] [Related]  

  • 31. The vexations of Vioxx.
    Sibbald B
    CMAJ; 2006 Feb; 174(4):444-5. PubMed ID: 16477046
    [No Abstract]   [Full Text] [Related]  

  • 32. Will Merck survive Vioxx?
    Simons J; Stipp D
    Fortune; 2004 Nov; 150(9):90-2, 94, 96-7 passim. PubMed ID: 15543824
    [No Abstract]   [Full Text] [Related]  

  • 33. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
    Bolten WW; Reiter S;
    Z Rheumatol; 2005 May; 64(4):286-9. PubMed ID: 15909092
    [No Abstract]   [Full Text] [Related]  

  • 34. Was Vioxx really that dangerous?
    Park A
    Time; 2005 Feb; 165(9):52. PubMed ID: 15765852
    [No Abstract]   [Full Text] [Related]  

  • 35. Under surveillance.
    Nat Biotechnol; 2005 Jan; 23(1):1. PubMed ID: 15637596
    [No Abstract]   [Full Text] [Related]  

  • 36. Lawsuits mount in wake of rofecoxib (Vioxx) withdrawal.
    Kondro W
    CMAJ; 2004 Nov; 171(11):1335. PubMed ID: 15557579
    [No Abstract]   [Full Text] [Related]  

  • 37. The law. Vioxx verdict: too little or too much science?
    Lawler A
    Science; 2005 Sep; 309(5740):1481. PubMed ID: 16141043
    [No Abstract]   [Full Text] [Related]  

  • 38. Cardiovascular complications of COX2 selective inhibitors cause considerable concern.
    Hedner T; Himmelmann A
    Blood Press; 2004; 13(5):260-1. PubMed ID: 15545147
    [No Abstract]   [Full Text] [Related]  

  • 39. Patient empowerment: rofecoxib revisited.
    Tannenbaum H
    J Rheumatol; 2006 Jun; 33(6):1033-5. PubMed ID: 16755647
    [No Abstract]   [Full Text] [Related]  

  • 40. What are the real lessons from Vioxx?
    Edwards IR
    Drug Saf; 2005; 28(8):651-8. PubMed ID: 16048352
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.